Overall treatment outcomes of the 51 patients with post-molar gestational trophoblastic neoplasia treated with chemotherapy
| Treatment | N | Results, n (%) | |
| Complete remission | Drug resistance | ||
| First-line chemotherapy | 51 | 32 (62.7) | 19 (37.3) |
| Act-D* | 25 | 16 | 9† |
| MTX-FA | 21 | 12 | 9 |
| 5-FU | 3 | 2 | 1 |
| FAV | 2 | 2 | 0 |
| Second-line chemotherapy | 19 | 16 (84.2) | 3 (15.8) |
| Act-D‡ | 8 | 7 | 1 |
| FAV | 5 | 3 | 2 |
| Etoposide +Act-D | 2 | 2 | 0 |
| EMA/CO | 4 | 4 | 0 |
| Third-line chemotherapy | 3 | 2 | 1 |
| EMA/CO | 3 | 2 | 1 |
| Fourth-line chemotherapy | 1 | 1 | |
| FAEV | 1 | 1 | |
*Five-day intravenous Act-D in 15 patients and biweekly pulsed intravenous Act-D in 10 patients.
†Five-day intravenous Act-D in 4 patients and biweekly pulsed intravenous Act-D in 5 patients.
‡All received biweekly pulsed intravenous Act-D.
Act-D, actinomycin D; MTX-FA: methotrexate with folinic acid; 5-FU, 5-fluorouracil; FAV, 5-FU+Act-D+vincristine; EMA/CO, etoposide +MTX+Act-D alternating with cyclophosphamide and vincristine; FAEV, 5-FU+Act-D+etoposide+vincristine.